InflaRx (NASDAQ:IFRX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of InflaRx (NASDAQ:IFRX) from a hold rating to a sell rating in a report published on Saturday morning.

Other analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday. HC Wainwright assumed coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a “buy” rating and a $6.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.20.

InflaRx Stock Up 2.5%

Shares of InflaRx stock traded up $0.03 on Friday, reaching $1.23. The stock had a trading volume of 20,990,261 shares, compared to its average volume of 582,194. The stock has a market capitalization of $82.57 million, a P/E ratio of -1.54 and a beta of 1.38. The company has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.18. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, meeting analysts’ consensus estimates of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Several hedge funds have recently bought and sold shares of IFRX. 683 Capital Management LLC increased its holdings in shares of InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares in the last quarter. Woodline Partners LP purchased a new position in shares of InflaRx in the 1st quarter valued at about $766,000. DAFNA Capital Management LLC acquired a new position in shares of InflaRx during the 1st quarter worth approximately $459,000. Adage Capital Partners GP L.L.C. acquired a new position in InflaRx during the second quarter worth $262,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after purchasing an additional 91,927 shares during the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.